Biorasi's Head of Safety Helms Training Sessions for Prestigious Industry Association

Miami, Oct. 31, 2017 -- Biorasi, a leading full-service global CRO, announced today that their V.P. of Drug Safety and Pharmacovigilance, Mark Vieder RPH MBA, co-lead Drug Safety training in a session entitled “Pragmatic Approaches to Drug Safety Across the Premarketing and Post Marketing Continuum” by top pharmaceutical industry association the Drug Information Association (DIA). Mr. Vieder held a well-received series of workshops, lectures, and seminars in Philadelphia over the course of four days from Oct. 23^rd through the Oct. 26^t. The event was part of the DIA’s thrice-yearly learning initiative and represents one of the cornerstones of the DIA’s mission to educate professionals in the drug development industry.

“We were very excited when Mark [Vieder] was selected to join the DIA faculty earlier this year, and even more so that he was picked to co-lead this session at the DIA training. Mr. Veider has elevated Biorasi into an even more influential pharmaceutical development company, and assisted in making our TALOS™ platform unrivaled in the areas of drug safety and pharmacovigilance. It’s fantastic that such well-regarded organizations as the DIA has recognized Mr. Vieder with this honor.” Said Boris Reznik, Ph.D., Chairman of Biorasi.

“At Biorasi, we deliver Clinical Research Optimized™” said Mr. Veider. “I’m honored that the DIA gave me an opportunity to teach our ‘Drug Safety and Pharmacovigilance, Optimized’ approach with the rest of the industry. Pharma is quickly realizing that novel approaches to safety management can be a powerful driving force in drug development programs. It’s exciting to be on the leading edge of that at Biorasi, and to get the opportunity to share my insights with the industry.”

About Biorasi:
Biorasi is an award-winning Clinical Research Optimized™ CRO. From study design to execution success, optimization is ingrained in TALOS™, the most robust and innovative trial management and optimization platform in the industry. Equipped with TALOS™, Biorasi’s full-service project teams have help pharmaceutical companies around the world develop numerous drugs, biologics and devices approved by the FDA, EMA and other regulatory agencies. Founded in 2002, Biorasi is headquartered in Miami, FL and has regional offices and operations across North America and around the world. It has been featured on the Inc. 500 list of the fastest growing US companies, and has received multiple awards for quality and service in pharmaceutical development.

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/f4b3f1a9-2c51-408f-9f1e-34e01ae64ab8

Alexandre Mouravskiy
Biorasi
1.786.888.1822
[email protected]